Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Helen Tomkinson

Showing results (11-20 of 26) with videos related to

Pageof 3
Sort By:
British Journal of Clinical Pharmacology|July 15, 2021
Improved characterization of the pharmacokinetics of acalabrutinib and its pharmacologically active metabolite, ACP-5862, in patients with B-cell malignancies and in healthy subjects using a population pharmacokinetic approachHelena Edlund, Francesco Bellanti, Huan Liu, et al.
Clinical Pharmacokinetics|October 26, 2018
Bridging Olaparib Capsule and Tablet Formulations Using Population Pharmacokinetic Meta-analysis in Oncology PatientsDiansong Zhou, Jianguo Li, Khanh Bui, et al.
Cancer Chemotherapy and Pharmacology|February 15, 2019
Gefitinib exposure and occurrence of interstitial lung disease in Japanese patients with non-small-cell lung cancerToshio Kawata, Mitsuo Higashimori, Yohji Itoh, et al.
Clinical Pharmacology and Therapeutics|December 27, 2018
Efficacy and Safety Exposure-Response Analyses of Olaparib Capsule and Tablet Formulations in Oncology PatientsDiansong Zhou, Jianguo Li, Maria Learoyd, et al.
Cancer Chemotherapy and Pharmacology|May 24, 2012
Single- and multiple-dose pharmacokinetics, safety and tolerability of zibotentan (ZD4054) in Chinese men with advanced solid tumorsJin Li, Yanfei Liu, Jun Qian, et al.
Pharmacology Research & Perspectives|April 28, 2025
Population Pharmacokinetics of Osimertinib in Patients With Non-Small Cell Lung CancerMartin Johnson, Yu-Wei Lin, Henning Schmidt, et al.
British Journal of Clinical Pharmacology|August 19, 2024
Exposure-response modelling of osimertinib in patients with non-small cell lung cancerMartin Johnson, Yu-Wei Lin, Henning Schmidt, et al.
Journal for Immunotherapy of Cancer|March 1, 2018
Radiation and PD-(L)1 treatment combinations: immune response and dose optimization via a predictive systems modelYuri Kosinsky, Simon J Dovedi, Kirill Peskov, et al.
Journal of Clinical Pharmacology|July 1, 2021
Physiologically Based Pharmacokinetic Modeling for Selumetinib to Evaluate Drug-Drug Interactions and Pediatric Dose RegimensSarit Cohen-Rabbie, Li Zhou, Karthick Vishwanathan, et al.
Cancer Chemotherapy and Pharmacology|April 27, 2021
Population pharmacokinetics and exposure-response of selumetinib and its N-desmethyl metabolite in pediatric patients with neurofibromatosis type 1 and inoperable plexiform neurofibromasStein Schalkwijk, Li Zhou, Sarit Cohen-Rabbie, et al.
Pageof 3

Showing results (11-20 of 26) with videos related to

Sort By:
Pageof 3
British Journal of Clinical Pharmacology|July 15, 2021
Improved characterization of the pharmacokinetics of acalabrutinib and its pharmacologically active metabolite, ACP-5862, in patients with B-cell malignancies and in healthy subjects using a population pharmacokinetic approachHelena Edlund, Francesco Bellanti, Huan Liu, et al.
Clinical Pharmacokinetics|October 26, 2018
Bridging Olaparib Capsule and Tablet Formulations Using Population Pharmacokinetic Meta-analysis in Oncology PatientsDiansong Zhou, Jianguo Li, Khanh Bui, et al.
Cancer Chemotherapy and Pharmacology|February 15, 2019
Gefitinib exposure and occurrence of interstitial lung disease in Japanese patients with non-small-cell lung cancerToshio Kawata, Mitsuo Higashimori, Yohji Itoh, et al.
Clinical Pharmacology and Therapeutics|December 27, 2018
Efficacy and Safety Exposure-Response Analyses of Olaparib Capsule and Tablet Formulations in Oncology PatientsDiansong Zhou, Jianguo Li, Maria Learoyd, et al.
Cancer Chemotherapy and Pharmacology|May 24, 2012
Single- and multiple-dose pharmacokinetics, safety and tolerability of zibotentan (ZD4054) in Chinese men with advanced solid tumorsJin Li, Yanfei Liu, Jun Qian, et al.
Pharmacology Research & Perspectives|April 28, 2025
Population Pharmacokinetics of Osimertinib in Patients With Non-Small Cell Lung CancerMartin Johnson, Yu-Wei Lin, Henning Schmidt, et al.
British Journal of Clinical Pharmacology|August 19, 2024
Exposure-response modelling of osimertinib in patients with non-small cell lung cancerMartin Johnson, Yu-Wei Lin, Henning Schmidt, et al.
Journal for Immunotherapy of Cancer|March 1, 2018
Radiation and PD-(L)1 treatment combinations: immune response and dose optimization via a predictive systems modelYuri Kosinsky, Simon J Dovedi, Kirill Peskov, et al.
Journal of Clinical Pharmacology|July 1, 2021
Physiologically Based Pharmacokinetic Modeling for Selumetinib to Evaluate Drug-Drug Interactions and Pediatric Dose RegimensSarit Cohen-Rabbie, Li Zhou, Karthick Vishwanathan, et al.
Cancer Chemotherapy and Pharmacology|April 27, 2021
Population pharmacokinetics and exposure-response of selumetinib and its N-desmethyl metabolite in pediatric patients with neurofibromatosis type 1 and inoperable plexiform neurofibromasStein Schalkwijk, Li Zhou, Sarit Cohen-Rabbie, et al.
Pageof 3